Table 5 Reports of SBRT for clinically diagnosed early-stage lung cancer

Inoue et al. [7]

Retrospective

T1-2a

115 (100)

0 (0)

14

3-year OS: 89.8% (T1a), 60.7% (T1b/T2a); 5-year OS: 89.8% (T1a), 53.1% (T1b/T2a)

Verstegen et al. [12]

Retrospective

T1-2

382 (65)

209 (35)

29.5 and 32.8

3-year OS: 55.4% vs. 53.7% (p = 0.99); 3-year LC: 91.2% vs. 90.4% (p = 0.982)

Takeda et al. [14]

Retrospective

T1-4

58 (34)

115 (66)

20.2 and 21.2

3-year LC: 80% vs. 87% (p = 0.73), 3-year PFS: 64% vs. 67% (p = 0.45), 3-year CSS: 74% vs. 71% (p = 0.57), 3-year OS: 54% vs. 57% (p = 0.48)

Sakanaka et al. [9]

Retrospective

T1-2a

37 (100)

0 (0)

39

3-year LC: 95.2% (T1a) and 91.7% (T1b/T2a), 3-year OS: 89.7% (T1a) and 49.3% (T1b/T2a)

Harkenrider et al. [8]

Retrospective

T1-2

34 (100)

0 (0)

16.7

2-year regional control: 80%, 2-year distant control: 85%, 2-year OS: 85%

Yoshitake et al. [10]

Retrospective

T1-2a

88 (100)

0 (0)

23

3-year LC: 90%, 3-year PFS: 67%, 3-year OS: 80%

Shaikh et al. [12]

Retrospective

T1-2a

651 (9)

6399 (91)

17

5-year OS: 21.2% vs. 21% (p = 0.872), 5-year CSS: 48.8% vs. 38.1%(p = 0.013)

Dautruche et al. [11]

Retrospective matched-cohort analysis

T1-3

131 (50)

131 (50)

26

3-year LC:85% vs. 80% (p = 0.78), 3-year OS:71% vs. 74% (p = 0.48)

Fernandez et al. [26]

Multi-institutional retrospective

T1-3

248 (33)

504 (67)

44

5-year LC: 93.2% vs. 87.9% (p = 0.10), 5-year DFS: 43.9% vs. 46.5% (p = 0.64), 5-year CSS: 87.0% vs. 86.6% (p = 0.43), 5-year OS: 60.0% vs. 62.2% (p = 0.24)

Zhang et al. [27]

Multi-institutional Propensity-Matched Analysis

T1-2

45 (50)

45 (50)

58.3 and 56.3

5-year LC: 89.8% vs. 85.5% (p = 0.50), 5-year PFS: 70.9% vs. 40.6% (p = 0.008), 5-year OS: 76.1% vs. 63.2% (p = 0.14)

Fan et al. this study

Retrospective

T1-2

55 (46)

64 (54)

69

5-year LC: 87% vs. 83% (p = 0.58), 5-year PFS: 48% vs. 45% (p = 0.82), 5-year CSS: 87% vs. 84% (p = 0.65), 5-year OS: 60% vs. 63% (p = 0.79)